文献速递慢性肾脏病肾小球疾病遗传性与小管间质肾病

SGLT2抑制剂在Alport综合征患者中的应用

SGLT2-Inhibition in Patients With Alport Syndrome.
PubMed 文献 · Kidney Int Rep · 2024-09-24

该多中心国际观察性研究纳入112例Alport综合征患者,评估启动SGLT2抑制剂后的安全性及疗效。主要终点为尿白蛋白/肌酐比值变化。结果显示启动SGLT2i后前三次随访(1–3、4–8、9–15个月)白蛋白尿较基线显著降低>30%,71患者年中共报告0.24次不良事件/患者年。结论提示在RAS抑制剂基础上SGLT2i可能减少Alport综合征患者白蛋白尿,长期对CKD进展的影响尚待研究。

要点

  • Alport综合征患者启动SGLT2i后1–15个月内白蛋白尿较基线显著降低>30%。
  • 随访71患者年不良事件率为0.24次/患者年,安全性可接受。
  • SGLT2i对Alport综合征长期肾脏结局的影响尚需进一步研究。

核心结论

  • 在RAS抑制剂基础上加用SGLT2i可能减少Alport综合征患者的白蛋白尿,但长期对CKD进展及肾衰竭的影响尚待研究。

研究设计与样本

  • 观察性、多中心、国际研究(NCT02378805),纳入112例启动SGLT2i的Alport综合征患者,主要终点为白蛋白/肌酐比值较治疗起点的变化。

主要发现

  • 成人患者年龄38±14岁,eGFR 63±35 ml/min per 1.73 m2(n=98),最长随访32个月。
  • 启动SGLT2i后第1–3、4–8、9–15个月随访时白蛋白尿(mg白蛋白/g肌酐)较基线显著降低>30%。
  • 启动SGLT2i近1年时eGFR平均下降9±12 ml/min per 1.73 m2(n=35)。
  • 共71患者年风险暴露中,SGLT2i治疗期间不良事件为0.24次/患者年。

临床怎么用

  • 对Alport综合征患者,可考虑在RAS抑制剂基础上加用SGLT2i以降低白蛋白尿,并监测eGFR变化与不良事件。

局限性

  • 为观察性研究,缺乏对照组,样本量有限,随访时间较短,长期肾脏结局尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Large-scale trials showed positive outcomes of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in adults with chronic kidney disease (CKD). Whether the use of SGLT2i is safe and effective in patients with the common hereditary CKD Alport syndrome (AS) has not yet been investigated specifically in larger cohorts. METHODS: This observational, multicenter, international study (NCT02378805) assessed 112 patients with AS after start of SGLT2i. The study's primary end point was change of albuminuria in albumin/g creatinine from the start of therapy. RESULTS: Compared to randomized trials investigating the effect of SGLT2i in CKD, the adult patients in this study were younger (aged 38 ± 14 years) and had a better estimated glomerular filtration rate (eGFR, 63 ± 35 ml/min per 1.73 m2; n = 98). Maximum follow-up was 32 months. Compared to baseline, at the first 3 follow-up visits (months 1 to 3, 4 to 8, and 9 to 15) after initiation of SGLT2i therapy, a significant reduction of albuminuria in mg albumin/g creatinine (>30%) was observed. Mean loss of eGFR was 9 ± 12 ml/min per 1.73 m2 almost 1 year after initiation of SGLT2i therapy (n = 35). At a total of 71 patient-years at risk, 0.24 adverse events (AEs) per patient-year on SGLT2i were reported. CONCLUSION: This study indicates that, additive to renin-angiotensin system (RAS)-inhibition (RASi), SGLT2i have the potential to reduce the amount of albuminuria in patients with AS. Future studies are needed to investigate the long-term effects of SGLT2i on CKD progression in patients with AS to assess whether the observed reduction in albuminuria translates to a delay in kidney failure (KF).

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Boeckhaus J, Gale DP, Simon J, et al. SGLT2-Inhibition in Patients With Alport Syndrome. Kidney Int Rep. 2024. PMID: 39698346. doi:10.1016/j.ekir.2024.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。